Global Chronic Kidney Disease (CKD) Drugs Market to 2025
DUBLIN, September 15, 2017 /PRNewswire/ --
The "Global Chronic Kidney Disease (CKD) Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been added to Research and Markets' offering.
The global Chronic Kidney Disease (CKD) Drugs market was valued at US$ 12.4 Bn in 2016, and is expected to reach US$ 17.4 Bn by 2025, expanding at a CAGR of 3.9% from 2017 to 2025.
There are different types of medications available in market. Medicines cannot reverse CKD, however they are used to treat complications and to slow further kidney damage. Factors such as rising incidence of cardiovascular disorders and diabetes, increasing geriatric population, significant unmet needs, promising pipeline molecule such as ABT-614 (Abbott laboratories), EOS789 (Chugai Pharmaceutical) and increasing prevalence of CKD would further drive the growth of CKD drugs market globally.
However, preferable use of generic drugs and in some countries may negatively impacting the market growth. For the purpose of study, global chronic kidney disease (CKD) drugs market is categorized on the basis of drug class such as antihypertensive, antihyperlipidemic, anemia treatment medications, swelling and other treatment medications. It is observed that, in the base year 2016, antihypertensive held largest market share because high blood pressure is major complication associated with CKD.
Currently, CKD drugs market is dominated by North America, due to factors such as higher cost of medication, changing healthcare reimbursement environment and upsurge in funding by government agencies and private organizations in healthcare system driving the growth of CKD drugs market in North America. It is estimated that Asia Pacific will grow at fastest CAGR during forecast period due to the factors such as increasing incidence of diabetes and hypertension, continues development in economic conditions, increase in health care spending, populous countries and developing healthcare infrastructure would drive market growth in Asia Pacific during forecast period.
The Chronic Kidney Disease (CKD) Drugs market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as AbbVie, Inc., Allergan plc. Amgen Inc., AstraZeneca plc., F. Hoffmann-La Roche Ltd, FibroGen, GlaxoSmithKline plc., Johnson & Johnson, Keryx Biopharmaceuticals, Inc., Kissei Pharmaceutical Co. Ltd., Pfizer, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd. and other.
Key Market Movements:
- Factors such as rising incidence of CKD, increasing geriatric population, favorable reimbursement policies in some countries and high degree of R&D activity in development of CKD drugs are driving the market growth globally.
- Due to the high unmet needs, manufacturers in the market are focusing on innovation and technological advances in treatment, this would further influence the market growth of CKD drugs globally.
- However, poor patient compliance in some countries and preferable use of generic drugs would negatively impact market growth of CKD Drugs.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Executive Summary
2.1 Global Chronic Kidney Disease (Ckd) Drugs Market Snapshot
2.2 Global Chronic Kidney Disease (Ckd) Drugs Market, by Drug Class, 2016 (US$ Bn)
2.3 Global Chronic Kidney Disease (Ckd) Drugs Market Share, by Geography, 2016 (Value %)
Chapter 3 Chronic Kidney Disease (Ckd) Drugs Market Analysis
3.1 Global Chronic Kidney Disease (Ckd) Drugs Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
18.104.22.168 High Prevalence of Chronic Kidney Disease (Ckd)
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Chronic Kidney Disease (Ckd) Drugs Market
Chapter 4 Global Chronic Kidney Disease (Ckd) Drugs Market, by Drug Class
4.4 Anemia Treatment Drugs
4.5 Swelling Treatment Drugs
Chapter 5 Global Chronic Kidney Disease (Ckd) Drugs Market, by Geography
Chapter 6 Company Profiles
6.1 Abbvie, Inc
6.2 Allergan Plc
6.3 Amgen Inc
6.4 Astrazeneca Plc
6.5 F. Hoffmann-La Roche Ltd
6.7 Glaxosmithkline Plc
6.8 Johnson & Johnson
6.9 Keryx Biopharmaceuticals, Inc
6.10 Kissei Pharmaceutical Co., Ltd
6.11 Pfizer, Inc
6.12 Sanofi S.A
6.13 Teva Pharmaceutical Industries Ltd
For more information about this report visit https://www.researchandmarkets.com/research/hqhzn4/global_chronic
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716